This phase II trial studies how well prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans (in combination with bone scans) work in selecting patients for Ra-223 radiation therapy that have castration-resistant prostate cancer that has spread from where it first started (primary site) to the bones (bone metastasis). Ra-223 is a type of therapy that emits radiation. Radiation gives off energy which can kill tumor cells and other cells that may support the tumor cells. Ra-223 is given by infusion into the veins, where it is absorbed by the bones. PSMA PET is a type of scan used to detect prostate cancer tumors. PSMA is a radioactive tracer that binds to a specific protein that is found on prostate tumor cells. The PSMA tracer shows the areas on the PET scan where tumor cells are active. A PET scan uses a special camera to detect the energy given off from radioactive tracers (such as PSMA) to make detailed pictures of areas where the tracer accumulates in the body. The PET scan is often combined with a magnetic resonance imaging (MRI) or computed tomography (CT) scan, which helps to map the locations where PSMA has accumulated. PSMA PET scans may be able to select patients that will benefit the most from Ra-223 treatment.

Start Date01 Oct 2024

Sponsor / Collaborator

The University of California, San Francisco

[+1]

ChiCTR2400081046 / SuspendedNot ApplicableIIT

Early diagnosis of bone metastases with 99mTc-MDP SPECT whole-body scan based on imaging radiomics, deep learning and vision Transformer classification model

Start Date29 Feb 2024

Sponsor / Collaborator-

ChiCTR2200064951 / SuspendedEarly Phase 1IIT

Clinical study on the effect of 99Tc MDP in the treatment of ischemic necrosis of lunate bone

Start Date30 Oct 2022

Sponsor / Collaborator

Shanghai No. 10 People's Hospital

100 Clinical Results associated with Technetium(99mTc)Methylenediphosphonate

100 Translational Medicine associated with Technetium(99mTc)Methylenediphosphonate

100 Patents (Medical) associated with Technetium(99mTc)Methylenediphosphonate

2,481

Literatures (Medical) associated with Technetium(99mTc)Methylenediphosphonate

01 Dec 2024·Clinical Nuclear Medicine

Radiation Pneumonitis With 99mTc-MDP Uptake in a Patient With Breast Cancer

Article

Author: Rabani Banou, Faeze ; Samadi, Mohammad Hadi ; Barashki, Somaye ; Khezri, Susan ; Bai, Mina

AbstractWe present MDP bone scan findings of radiation pneumonitis in a 45-year-old woman with invasive ductal carcinoma of the right breast, classified as stage IIIa, T3N2M0. The patient underwent a modified radical mastectomy, neoadjuvant chemotherapy, and subsequent radiotherapy, receiving the last session 7 months before the bone scan. Whole-body images acquired 3 hours postinjection of 20 mCi (730 MBq) 99mTc-MDP showed incidentally increased uptake in the right hemithorax, confined to the lung parenchyma of the right lung on SPECT/CT images.

01 Dec 2024·Annals of Nuclear Medicine

SPECT/CT imaging: quantifying 99mTc-MDP concentration in the spine and pelvis

Article

Author: Liu, Guobing ; He, Yibo ; Shi, Hongcheng ; Chen, Shuguang ; Hou, Xiaoguang

OBJECTIVEThis study aimed to identify a relatively robust SUV for guiding clinical practice through quantitative measurement and comparison of various normalization methods based on the SUV of ^99mTc-MDP in the normal spine and pelvis using an integrated SPECT/CT scanner.METHODSBetween June 2017 and September 2019, a total of 500 oncology patients (mean age, 60.9; men, 66.0%) who underwent bone SPECT/CT scans with ^99mTc-MDP were enrolled in this retrospective study. The mean SUV (SUV_mean) of 4962 spinal and pelvic bones was calculated based on the patients' body weight (BW), lean body mass (LBM), bone mineral content (BMC), body surface area (BSA), and body mass index (BMI), defined as SUV_bw, SUV_lbm, SUV_bmc, SUV_bsa, and SUV_bmi, respectively. The coefficients of variation (CoVs) of the aforementioned parameters were compared, and the correlation and multiple linear regression analyses were used to compare the extent to which these parameters were affected by sex, age, height, weight, BMI, and CT values.RESULTSThe average SUVs in the normal spine and pelvis displayed a relatively wide variability: 4.573 ± 1.972 for SUV_bw, 3.555 ± 1.517 for SUV_lbm, 0.163 ± 0.071 for SUV_bmc, 0.124 ± 0.052 for SUV_bsa, and 1.668 ± 0.732 for SUV_bmi. In general, SUV_bsa had relatively lowest CoV (42.1%) in all vertebrae and pelvis compared with other SUVs. For correlation analyses, all SUVs displayed weak but significant correlations with age and CT values. For regression analyses, SUV_bsa was influenced only by age, BMI, and CT values independently. The effects of these variables on SUV_bsa were all smaller than those on conventional SUV_bw.CONCLUSIONSThe SUVs of ^99mTc-MDP in normal bone derived from quantitative bone SPECT/CT could serve as a reference for evaluating tumor bone metastasis, but it should be assessed on a site-specific basis. SUV_bsa exhibited superior robustness among all the SUV normalization variations, indicating potential clinical applications.

01 Nov 2024·Applied Radiation and Isotopes

Direct radiolabeling of Folate with Tc-99m using QbD approach: A step closer to folate based diagnostic agent

Article

Author: Nabar, Swapna J. ; Upadhaya, Prashant G. ; Nabar, Swapna J ; Upadhaya, Prashant G

The aim of the presented work was to develop folate based radiolabeled compound intended to be used as diagnostic aid for the various folate-receptor overexpressing cancers eg. breast cancer, brain tumors, lung cancer etc. Folate was directly radiolabeled with Tc-99m using Quality-by-Design and encapsulated in micellar nanocarriers. The authors are of the view that the stable radiolabeled folate could be of potential diagnostic value in cancers overexpressing folate receptors thereby opening novel possibilities to diagnostic applications of radiolabeled folate. SUMMARY FOR TECHNICAL NOTES: Folic acid was directly radiolabeled with Tc-99m utilizing a quality by design approach. The experimental trials were designed using the Box-Behenken design with the concentration of drug, concentration of reducing agent and the incubation time as dependent variable and percent radiolabeling as the response for the same. The applied design in the method section was validated with a series of experiments and the percent labeling of the FA with Tc-99m was found to be around 94%. The radiolabeled compound was imperilled to stability evaluation by incubating the same with serum and physiological pH and the same was found to be stable at the end of 4h. On subjecting to DTPA challenge test, the compound displayed no change in the radiolabeling percentage thereby indicating the robustness of the formed Tc-99m-FA complex, The radiolabeled Tc-99m-FA was further encapsulated into micellar nanocarriers and the same were also found to be robust and stable.

News (Medical) associated with Technetium(99mTc)Methylenediphosphonate

25 Jun 2024

·www.biospace.com

Radiopharmaceutical Industry Outlook: Growth Trends and Future Prospects

The concept of radiopharmaceuticals has been around for several decades. The field of radiotherapeutics has seen rapid development due to advances in radioisotope-based therapies, multimodality bioimaging technology, nanotherapeutics, and interventional oncology. The success of Novartis' prostate cancer drug Pluvicto further led to the resurgence of interest among prominent players in the field, leading to numerous clinical trials testing novel radiotheranostics. What are radiopharmaceuticals, and what are some statistics about the procedures performed globally? Radiopharmaceutical is a combination of radioactive isotopes and pharmaceutical drugs. They are used to diagnose and treat life-threatening diseases such as cancer, cardiac disorders, and neurological disorders. They are utilized in 3 procedures: SPECT imaging, PET imaging and therapeutics. Radiopharmaceuticals are transforming the treatment of various diseases, especially cancers, with targeted radionuclide therapy. Radioligand therapy targets cancer cells with high doses of radiation, promising advancements in cancer treatment. The widespread use of nuclear medicines is evident from a number of procedures performed globally. According to the World Nuclear Association, the annual number of nuclear medicine procedures performed exceeds 50 million, and the need for radioisotopes is rising. Radioisotopes are employed in the medical field by more than 10,000 hospitals worldwide, with approximately 90% of the procedures being diagnostic. Technetium-99 (Tc-99m) is the most often used radioisotope in nuclear medicine diagnostics; it is utilized in approximately 80% of nuclear medicine procedures and 85% of diagnostic scans performed globally. Additionally, in the US and Europe, 20 million and about 10 million nuclear medicine procedures are performed annually, respectively, with 2 million being therapeutic. SPECT is the current major scanning technology employed to diagnose and monitor a wide range of medical conditions; however, PET is expected to be preferred in future over SPECT as it is a more precise and sophisticated technique in the diagnosis of cancers and is well-used in cardiac and brain imaging. Tc-99m and 18F- FDG are the major radiopharmaceuticals for SPECT and PET imaging, which account for 80% of all nuclear medicine procedures. However, the availability of new radiopharmaceuticals, such as PET imaging agents flutemetamol and florbetapir used in neurological conditions and cancer theranostic, drive molecular imaging in the clinical setting. Read our related market research report’s key insights: Radiopharmaceutical CDMO/CMO Services Market Key Insights 2024 Radiotheranostics Market Key Insights 2024 Radiopharmaceuticals Market Key Insights 2024 Radioligand Therapy Market Key Insights 2024 Radioactive Tracer Market Key Insights 2024 What are the different components of the radiopharmaceuticals market: Radioligand therapy, nuclear pharmacy, radiotheranostics, and radioactive tracers are various components used in radiopharmaceuticals to diagnose and treat diseases. The increasing utilization of these components drives substantial growth in the radiopharmaceutical industry. With rising demand for targeted cancer treatments, advanced diagnostic procedures, and integrated therapeutic solutions, these segments play pivotal roles in expanding the market. As technological innovations continue to enhance precision and efficiency, the radiopharmaceutical industry is poised for sustained growth and global expansion in the coming years. Radioligand Therapy/ Radiopharmaceutical Therapeutics Radioligand therapy (RLT) utilizes targeted medicines, often employing radioactive isotopes like lutetium-177, to bind to tumour targets, offering high rates of long-term tumour remission and stability, particularly for metastasized disease. Nuclear Pharmacy Nuclear pharmacy, a pharmacy subspecialty, focuses on preparing, dispensing, and managing radioactive materials used in nuclear medicine operations. Radiotheranostics Radiotheranostics uses radioactive probes to diagnose and treat specific cells, usually cancer cells. It's a combination of molecular imaging and targeted therapy that uses a ligand-linker-radioisotope design. Radioactive Tracer Radioactive tracers are diagnostic radiopharmaceuticals used to image the body and identify diseases. These are composed of tightly bonded molecules with a radioactive atom. So, what are the market dynamics of the Radiopharmaceutical industry? Key driving factors: Advancements in imaging technology Growth in PET imaging procedures driven by prostate, cardiac, and amyloid imaging due to better imaging, significantly lower false negatives and faster examination time Diagnostic and therapeutic application expansion of radiopharmaceuticals in new applications such as cardiology, neurology apart from oncology The ageing population and rising prevalence of target diseases increase the target population Availability of new products in PET and Theranostics segment Expansion of radioligand therapy into earlier lines of treatment (i.e., from 3L to include 2L, 1L and mHSPC populations) Innovative use of AI to enhance diagnostic accuracy and prognostics Rising demand for targeted cancer treatments Measures to close the gap between supply and demand for Mo-99 Market restraints: Stringent manufacturing and regulatory environment Requirement of robust raw material supply, manufacturing, and product transportation due to the short half-life of products Lack of skilled workforce Preconceived negative perceptions around the use of radioactive substances Trends - Investigation of new/ alternative radioisotopes such as 211 At, 223 Radium, and 212 Lead Supply chain advancements Integration with AI for diagnostic imaging Availability of radionuclide therapy programs in hospitals and cancer centers The radiopharmaceuticals sector is highly specialized, competitive and rapidly growing. Cardinal, GE, Novartis, Curium, and Jubilant are some of the prominent players in the industry. Major industry players are acquiring smaller companies with radiopharmaceuticals pipelines and investing in potential blockbuster products to get a foot in the door, which has resulted in significant investments, M&A, and funding. This can be attributed to the effectiveness of radiopharmaceuticals in cancer treatment and the commercial success of recently approved products such as Lutathera (Novartis) and Pluvicto (Novartis). In March 2024, AstraZeneca PLC completed the Canadian biotech Fusion Pharmaceuticals Inc. acquisition for $2 billion. In May 2024, Novartis AG acquired Mariana Oncology to enhance its research capabilities and clinical supply capacity in radioligand therapies. Similarly, in December 2023, Eli Lilly acquired POINT Biopharma Global Inc. with its lutetium-based portfolio for $ 1.4 billion. That same month, BMS purchased RayzeBio, Inc., including its Phase III actinium-based RYZ101, for $4.1 billion. Additionally, radiopharmaceuticals are being developed by significant drugmakers, a few publicly traded companies, and at least a dozen biotechnology startups. The under-development pipeline includes several PET & SPECT imaging agents, and targeted theranostic radiopharmaceuticals for diagnosing cancer and non-cancer indications. For instance, Clarity Pharmaceuticals, an innovative radiopharmaceutical with its Targeted Copper Theranostic (TCT) platform of products, has SARTATE, SAR-bisPSMA, and SAR-Bombesin, next generation, highly targeted theranostic radiopharmaceutical for cancer. GE Healthcare has two new radiopharmaceuticals in the pipeline, PET and SPECT imaging. Expanding the radiopharmaceutical pipeline presents a substantial opportunity for improved patient care with increased access to cutting-edge imaging, improved treatment options, greater personalized treatment, lower radiation exposure, and potential for future advancements. Radioligand therapy is currently used in a small number of cancers. It appears to be a promising treatment option, and its use is anticipated to increase over time to treat various cancer types. The radiopharmaceutical market growth will be further boosted by the use of radioligand therapy together with other therapies, raising patient and healthcare professional awareness of radioligand therapy, coordinating and collaborating specialities involved in providing cancer care (medical oncologists, nuclear medicine physicians, and others), planning hospital capacity—both human and physical—to deliver radioligand therapy safely and effectively, and developing efficient nuclear waste disposal protocols tailored to the various types of therapy.

AcquisitionPhase 3Radiation Therapy

01 Feb 2023

·www.biospace.com

BWXT Medical and Laurentis Complete Key Tc-99m Generator Program Milestone

OTTAWA, Ontario--(BUSINESS WIRE)-- Life-saving Molybdenum-99 (Mo-99) isotopes can now be produced at Ontario Power Generation’s (OPG) Darlington Nuclear Generating Station, thanks to the installation and initial commissioning of an innovative isotope system by Laurentis Energy Partners and BWXT Medical Ltd. (NYSE: BWXT). The production of Mo-99 at Darlington will be a world-first for a commercial power reactor. With the necessary equipment now installed, the team will continue with planned commissioning and preparation activities for commercial production of Mo-99, pending completion of validation runs and approval from the U.S. Food and Drug Administration (FDA) and Health Canada. Mo-99 is used to produce Technetium-99 metastable (Tc-99m), one of the most prevalently used diagnostic imaging agents in nuclear medicine, which helps detect illnesses like cancer and heart disease. Tc-99m is delivered to radiopharmacies and hospitals across North America to make radiopharmaceuticals for patients. This production break-through will help resolve historical shortages of this vital product. Quick Facts: Because of the unique design of Darlington’s CANDU reactors, medical isotopes can be produced without interrupting the generation of clean energy. North America has not had a stable domestic supply of Mo-99 since Canada’s National Research Universal reactor ceased production in October 2016. Hospitals have had to rely on imports from Europe, Africa, and Australia. Once operational, the arrangement between Laurentis and BWXT Medical will be capable of producing enough Mo-99 to supply a significant portion of the current and future North American demand. Historically, Mo-99 has been produced within research reactors using uranium as a starting material. Alternatively, BWXT Medical’s Tc-99m generator will be produced using natural molybdenum targets irradiated at Darlington Nuclear, greatly reducing waste by-products. In the future, the newly-installed Target Delivery System (TDS) at Darlington may be used to produce other medical isotopes. With the addition of Mo-99, multiple isotopes are now produced at Darlington: Helium-3, Mo-99, and Tritium, with plans underway to produce Cobalt-60 – currently also extracted from reactors at Pickering. Quotes: “Tc-99m is the workhorse isotope for nuclear medicine,” said Dr. David Laidley, Nuclear Medicine Physician at London Health Sciences Centre. “Used in over 80 percent of all nuclear medicine procedures, the availability of this critical isotope will save countless lives.” “Ontario is leading the way on the production of medical isotopes, leveraging our world-class nuclear generation stations and supply chain,” said Todd Smith, Ontario’s Minister of Energy. “Production of Molybdenum-99 at Ontario's Darlington Nuclear Generating Station, a world-first for a commercial power reactor, will create a steady global supply of radiopharmaceuticals which help our healthcare system detect illnesses like cancer and heart disease." “This is an exciting milestone for all companies involved, but most importantly, for patients in need,” said Ken Hartwick, President and CEO of OPG. “Ontario’s nuclear generating stations have demonstrated for decades their value extends beyond producing reliable, affordable, clean energy. I’m proud of the role our employees and stations play in providing life-saving medical isotopes to the world.” “Completing the installation of the TDS at Darlington is a significant milestone for the Laurentis and BWXT team,” said Dr. Jonathan Cirtain, BWXT Medical Ltd. President and Chief Executive Officer. “This partnership leverages Darlington’s industry-leading operational reliability, the expertise of Laurentis and OPG to provide irradiation services, and BWXT’s proprietary neutron capture process and innovative production technology. It has been a collaborative and industry-leading effort.” “The installation of the TDS is the result of many years and countless hours of support from everyone involved at Laurentis, BWXT, OPG, and our other project partners,” said Jason Van Wart, President of Laurentis. “The entire team was tireless in their efforts to install this ground-breaking isotope irradiation system to secure a reliable, large-scale supply of a crucial diagnostic isotope that hospitals and patients so desperately need. As we continue to innovate and aspire to be a global leader in isotope production, I look forward to what our team and the industry will accomplish next.” Watch a video on how Ontario is leading the way in the production of Mo-99: To learn more about nuclear medicine capabilities and, specifically Tc-99m (2:44), click here: About Laurentis Energy Partners Laurentis Energy Partners, a subsidiary of Ontario Power Generation, provides solutions for customers across energy markets and in health care around the world, offering expertise in inspections, refurbishment and engineering, nuclear materials sorting and recycling, the production of nuclear isotopes, and the advancement of small modular reactors. Laurentis has offices in the Greater Toronto Area, Hamilton and Bruce County in Ontario, Saint John in New Brunswick, and Bucharest and Cernavoda in Romania. About OPG As one of North America’s largest, most diverse electricity generators, OPG invests millions in local economies and employs thousands of people across Ontario and the US. OPG and its family of companies are leading the development of new technologies, refurbishment projects, and electrification initiatives to power the growing demand of a clean economy. Learn more about how the company is advancing these initiatives while prioritizing people, partnerships, and strong communities by reading OPG’s Climate Change Plan, Reconciliation Action Plan, and Equity, Diversity, and Inclusion (ED&I) strategy. About BWXT Medical Ltd. BWXT Medical Ltd. manufactures custom radiopharmaceuticals, radiotherapies and medical isotopes. BWXT Medical is a subsidiary of BWX Technologies, Inc. (NYSE: BWXT). BWXT is a Fortune 1000 and Defense News Top 100 manufacturing and engineering innovator that provides safe and effective nuclear solutions for global security, clean energy, environmental remediation, nuclear medicine and space exploration. Follow us on Twitter at @BWXT and learn more at . Forward Looking Statements BWXT cautions that this release contains forward-looking statements, including statements relating to the production, performance, timing, impact and value of Tc-99m and changes in demand, benefit and applicability of Tc-99m. These forward-looking statements involve a number of risks and uncertainties, including, among other things, changes in market demand for, delays in and commercialization of our Tc-99m production; our ability to obtain the necessary regulatory approvals, licenses and permits in a timely manner; the ability to commercialize this product; competition in an environment of rapid technological change; and the enforcement and protection of our intellectual property rights. If one or more of these or other risks materialize, actual results may vary materially from those expressed. For a more complete discussion of these and other risk factors, please see BWXT’s annual report on Form 10-K for the year ended December 31, 2021 and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. BWXT cautions not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and undertakes no obligation to update or revise any forward-looking statement, except to the extent required by applicable law.

Radiation Therapy

14 Oct 2021

·www.biospace.com

ARTMS Inc. Announces Health Canada Submission for Ga-68 Production and Tri-party Collaboration to Advance Ga-68 Imaging Products

BURNABY, British Columbia--(BUSINESS WIRE)-- ARTMS Inc. (ARTMS), the global leader in developing and commercializing novel products enabling cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce the submission of a Type 1 Master File with the Health Products & Food Branch, Health Canada (HC) for the production of gallium-68 (Ga-68). Gallium-68 is a critical medical isotope of significant clinical importance in nuclear medicine diagnostic procedures utilizing Positron Emission Tomography (PET) imaging. ARTMS’ Health Canada filing will help alleviate the current supply constraints and provide innovators the ability to advance new radiopharmaceutical drugs into development. On the basis of the filing, ARTMS has also entered into a tri-party co-operation with fellow industry leaders, POINT Biopharma (NASDAQ: PNT) and the Canadian Molecular Imaging Probe Consortium (CanProbe), a joint venture between the Centre for Probe Development and Commercialization (CPDC) and the University Health Network (UHN), for the development and clinical use of innovative radiopharmaceuticals in Canada. “The Ga-68 regulatory filing in Canada is the next step in ARTMS’ goal to prevent the significant supply issues of this important medical isotope. The current supply chain of germanium/gallium generators is inefficient, high cost and at risk for interruption at any time. Any interruptions to the supply chain will negatively impact patients and drug innovators,” explained Charles S. Conroy, Chief Executive Officer of ARTMS. “Our collaborative working relationship with POINT and CanProbe will leverage ARTMS’ proprietary solid target approach to bring important new medicines to Canadians.“ “Increasing the availability and scale of Ga-68 supply through cyclotron production will be important in further accelerating the development and commercialization of next generation radiopharmaceutical therapies,” said Dr. Joe McCann, Chief Executive Officer of POINT Biopharma. “We believe ARTMS’ solid target approach to Ga-68 production will play a key role in increasing the availability of this important isotope. We are excited to work with ARTMS and CanProbe in the creation of POINT’s new Ga-based based molecular imaging agents that will enable the development and commercialization of our next generation radiopharmaceutical therapies.” Dr. Bruno Paquin, President of CanProbe and CEO of CPDC, remarked, “Gallium-68 is the critical active component of many radiopharmaceuticals used in the diagnosis and staging of important medical conditions such as prostate cancer and neuroendocrine tumours.” Dr. Paquin further commented that, “ARTMS’ QUANTM Irradiation System enables our facility a 100-fold increase in the availability of Ga-68 over the current generator supply. This significant increase in isotope supply directly impacts our ability to work with innovators such as POINT to meet end-patient needs.” ARTMS continues to drive nuclear medicine’s supply chain into the future through the QUANTM Irradiation System ecosystem by providing a pathway for large scale isotope production of Zr-89, Cu-64 and Tc-99m. Mr. Conroy concluded, “We will continue to support and work with radiopharmaceutical innovators to validate their products with the ARTMS system and have their regulatory filings reference ARTMS’ cyclotron solid target approaches.” About ARTMS Based in Burnaby, British Columbia, Canada, ARTMS Inc. is a global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world’s most-used diagnostic imaging isotopes. ARTMS’ flagship product, the QUANTM Irradiation SystemTM (QISTM), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium‐99m (99mTc) and copper-64 (64Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry. For more information on the QUANTM Irradiation System™ and ARTMS, please follow us on Twitter @ARTMS_Inc and LinkedIn and visit . About POINT Biopharma POINT Biopharma Global Inc. (NASDAQ: PNT) is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), and industry-leading manufacturing capabilities and supply chain, to revolutionize theragnostic drug development and radioligand commercialization. Learn more about POINT Biopharma Global Inc. at . About CanProbe CanProbe is a joint venture between the Centre for Probe Development and Commercialization (CPDC) and University Health Network (UHN) to create a Canadian Centre of Excellence for the development, translation, utilization and commercialization of radiopharmaceuticals. CanProbe leverages the strengths of its partners and their affiliates. For more information about CanProbe, please visit: . The Centre for Probe Development and Commercialization (CPDC) is a global leader in the discovery, development and commercialization of next generation radiopharmaceuticals supported by the Networks of Centres of Excellence (NCE), McMaster University and the Ontario Institute for Cancer Research (OICR). With an established pipeline of products and a robust and reliable manufacturing unit, CPDC supplies innovative diagnostic and therapeutic radiopharmaceuticals globally ( ). University Health Network consists of Toronto General and Toronto Western Hospitals, the Princess Margaret Cancer Centre, Toronto Rehabilitation Institute, and The Michener Institute of Education at UHN. The scope of research and complexity of cases at University Health Network has made it a national and international source for discovery, education and patient care. It has the largest hospital-based research program in Canada, with major research in arthritis, cardiology, transplantation, neurosciences, oncology, surgical innovation, infectious diseases, genomic medicine and rehabilitation medicine. University Health Network is a research hospital affiliated with the University of Toronto.

100 Deals associated with Technetium(99mTc)Methylenediphosphonate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Technetium(99mTc)Methylenediphosphonate	V09BA02	DB09138

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bone metastases	CN	Guangdong CI Medicine Co.,Ltd.	01 Jan 1997
Contrast agents	CN	Guangdong CI Medicine Co.,Ltd.	01 Jan 1997
Osteogenesis Imperfecta	US	Jubilant Draximage, Inc.Startup	28 Nov 1978
Diagnostic agents	JP	PDRadiopharma, Inc.	01 Aug 1978

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2022	Not Applicable	-	-	99mTc-MDP (Patients with documented RPE)	nkgnrcgugp(putveofmaq) = No long-term dermatologic or oncologic adverse events were identified. uqbycunjuh (ianbumbcis ) View more	-	08 Aug 2022
NCT02304757 (CTgov)	Not Applicable	Differentiated Thyroid Gland Carcinoma \| Osteoporosis	142	99Tc-MDP (99Tc-MDP)	iudzkcdetf(crabbpzjql) = bsvkcpuxnp cipcnrvwug (kywrjxfowy, cfpkhkundh - yqqcehkslz) View more	-	18 Oct 2021
NCT02304757 (CTgov)	Not Applicable	Differentiated Thyroid Gland Carcinoma \| Osteoporosis	142	Fosamax (Fosamax)	iudzkcdetf(crabbpzjql) = tcgtggvqbl cipcnrvwug (kywrjxfowy, mokrzmrmdy - qlahnxktbi) View more	-	18 Oct 2021
SNMMI2020	Not Applicable	Chordoma	-	99m Tc-MDP (CT features)	qnasghgahj(brnevktdrp) = ldfqddjyfb fephtmlclc (zdcrnfczdn )	-	15 May 2020
SNMMI2020	Not Applicable	-	-	99m Tc-MDP (Normal BMD group)	mizcobyfww(vwrfijduok) = vudnyseugk arixtdvgqg (kkarztfkmy ) View more	-	15 May 2020
SNMMI2020	Not Applicable	-	-	99m Tc-MDP (Osteopenic group)	mizcobyfww(vwrfijduok) = bvqykdhkcl arixtdvgqg (kkarztfkmy ) View more	-	15 May 2020
SNMMI2019	Not Applicable	Bone Cancer	-	Tc-99m-MDP (Hemiarthroplasty prosthesis)	pkpbvnofip(hpijshmlwq) = umwgwuhbiq fzkvgfdksw (gfinjnosip )	-	21 May 2019
SNMMI2019	Not Applicable	Bone Cancer	-	Tc-99m-MDP (Epiphysis-minimal invasive endoprosthesis)	pkpbvnofip(hpijshmlwq) = ocutjwakdh fzkvgfdksw (gfinjnosip )	-	21 May 2019
SNMMI2018	Not Applicable	-	-	99m Tc-MDP99mTc-MDP (Patients undergoing 99mTc-MDP SPECT bone imaging)	nyqvhvfbln(cmpoahsqqd) = gimspekzpd fhwdjasfpi (fyyxkulzxv )	-	23 May 2018
NCT03002454 (CTgov)	Phase 3	Bone Cancer	4	99mTc MDP Injection:neutron-bombardment	xenfddxque(anqihhhkzi) = fvbkddpjea xolcdcytoc (cbdbmverbi, poxglxszzb - larplgtvnz) View more	-	03 Oct 2017
SNMMI2016	Not Applicable	Bone metastases	-	18F-NaF99mTc-MDP (18F-NaF PET/CT)	jbzvgpwzpj(caapmjgmtz) = hrtvefcrap lsygqvedmz (vszeofjpgz ) View more	-	24 May 2016
SNMMI2016	Not Applicable	Ossifying Fibroma	-	Tc-99m MDP (Solitary orbital hot lesions)	efpbfeatmd(jdevuxjtws) = aotkxrdkqa hlnxmddubn (vypthnwipy )	-	24 May 2016
SNMMI2015	Not Applicable	Head and Neck Neoplasms	-	Tc-99m MDP (MDP uptake in lymph nodes)	fvczuiiooy(epatrgawmy) = zduuwkpbpb xykgnpnaub (apmmcnkbpr )	-	15 May 2015
SNMMI2015	Not Applicable	Head and Neck Neoplasms	-	Tc-99m MDP (No MDP uptake in lymph nodes)	fvczuiiooy(epatrgawmy) = igugogttkf xykgnpnaub (apmmcnkbpr )	-	15 May 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis